Bicara therapeutics presents phase 1/1b dose expansion results with ficerafusp alfa in advanced squamous cancer of the anal canal at the 2025 asco gastrointestinal cancers symposium

Boston, jan. 27, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2l) or later squamous cancer of the anal canal (scac). the results were presented in a poster session during the 2025 asco gastrointestinal (gi) cancers symposium on saturday, january 25, 2025. ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (egfr) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (tgf-Β), and is being evaluated in multiple solid tumor types.
BCAX Ratings Summary
BCAX Quant Ranking